カテゴリ： GlobalData, アメリカ, 企業調査

Innovation Pharmaceuticals Inc (IPIX)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Innovation Pharmaceuticals Inc (IPIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C12328
◆発行会社（調査会社）：GlobalData
◆発行日：2018年12月
◆ページ数：79
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Innovation Pharmaceuticals Inc (Innovation Pharmaceuticals), formerly Cellceutix Corp, is a biopharmaceutical company that discovers and advances medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications. The company provides pipeline products such as kevetrin for the treatment of advanced solid tumors and acute myelogenous leukemia, among others. It offers pipeline products such as Brilacidin for the treatment of oral mucositis and skin infections; and Prurisol for the treatment of psoriasis. Innovation Pharmaceuticals works in collaboration with various research institutions across the US and other European countries. The company operates in the US. Innovation Pharmaceuticals is headquartered in Beverly, Massachusetts, the US.

Innovation Pharmaceuticals Inc (IPIX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Innovation Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Cellceutix Enters Into Agreement With University of Texas MD Anderson Cancer Center For Kevetrin Drug 13
Licensing Agreements 15
Cellceutix Enters Into Licensing Agreement For Cancer Compound 15
Equity Offering 16
Innovation Pharma to Raise up to USD10 Million in Private Placement of Shares 16
Innovation Pharma Raises USD2 Million in Private Placement of Shares 17
Innovation Pharma to Raise USD30 Million in Private Placement of Shares 18
Cellceutix Raises USD16 Million in Private Placement of Common Stock 19
Cellceutix Raises USD2.2 Million in Private Placement of Shares 20
Cellceutix Raises USD20 Million Private Placement Of Common Stock 21
Cellceutix Completes First Tranche Of Private Placement Of Common Stock For USD0.1 Million 22
Cellceutix Completes Private Placement Of Series a Convertible Preference Stock For US$1 Million 24
Acquisition 25
Cellceutix Completes Acquisition Of PolyMedix 25
Innovation Pharmaceuticals Inc – Key Competitors 26
Innovation Pharmaceuticals Inc – Key Employees 27
Innovation Pharmaceuticals Inc – Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Financial Announcements 29
Feb 16, 2017: Cellceutix Reports on Q2 Fiscal 2017, Prepares for Important Clinical Milestones 29
Product News 31
10/31/2017: Innovation Pharma Provides Update on Brilacidin 31
09/05/2018: Innovation Pharmaceuticals to present Brilacidin for inflammatory bowel disease at Inaugural “IBD Innovate 2018” Conference Hosted by the Crohn’ 32
01/29/2018: Innovation Pharmaceuticals Brilacidin Franchise Anchored in Three Clinical Indications — Oral Mucositis, Inflammatory Bowel Disease and Serious Skin Infections; Expands into Dermatologic Diseases 33
Clinical Trials 34
Jun 29, 2018: Innovation Pharmaceuticals Announces Database Lock for Phase 2b Trial of Oral Prurisol for Psoriasis 34
May 09, 2018: Innovation Pharmaceuticals Concludes Data Analysis of its Phase 2 Clinical Trial for Severe Oral Mucositis in Head and Neck Cancer; Positioning to Fill a Substantial Void in Supportive Cancer Care 35
Apr 16, 2018: Innovation Pharmaceuticals Data from Phase 2 Brilacidin Oral Mucositis Trial in Head and Neck Cancer Show Notable Reductions in Median Duration of Severe OM and in Number of Unplanned Visits/Hospital Admissions Due to OM 37
Apr 09, 2018: Innovation Pharmaceuticals Phase 2 Oral Mucositis Trial Additional Data Show Brilacidin-OM Demonstrated A Significant Reduction in the Incidence of Severe Oral Mucositis in Patients with Head and Neck Cancer (HNC) Receiving Aggressive Chemotherapy Regimen 38
Mar 15, 2018: Innovation Pharmaceuticals Views Brilacidin-OM as Clearly Differentiated Compared to Limited Competition for Preventing Severe Oral Mucositis 39
Jan 16, 2018: Innovation Pharmaceuticals Presents at 2018 Biotech Conference; Oral Mucositis Drug Candidate Garners Exceptional Interest After Successful Phase 2 Trial 41
Jan 03, 2018: Innovation Pharmaceuticals Brilacidin Meets Key Secondary Endpoint in Phase 2 Trial, Delays Onset of Severe Oral Mucositis (SOM) 42
Dec 21, 2017: Innovation Pharma Completes Final Patient Visit in Phase IIb Study of Oral Prurisol for Psoriasis 43
Dec 18, 2017: Innovation Pharmaceuticals Brilacidin Oral Mucositis Program Moving Forward Based Upon Positive Anchoring Phase 2 Results and Increased Brilacidin Franchise Value 44
Dec 11, 2017: Innovation Pharmaceuticals Reports Positive Topline Results from Phase II Placebo-Controlled Trial of Brilacidin for the Prevention of Oral Mucositis in Head and Neck Cancer Patients 45
Nov 30, 2017: Final Patient Completes Treatment in Innovation Pharmaceuticals Phase IIb Study of Oral Prurisol for Psoriasis 47
Nov 16, 2017: Innovation Pharmaceuticals Offers Perspectives on Brilacidin as a Potential Preventative Treatment for Oral Mucositis in Head and Neck Cancer Patients 48
Oct 31, 2017: Innovation Pharmaceuticals Phase 2b Psoriasis Study On-Track for Completion in December 2017 49
Oct 26, 2017: Innovation Pharmaceuticals Aims to Develop First Drug for Approval in Prevention of Oral Mucositis in Head and Neck Cancer Patients as Phase 2 Clinical Trial of Brilacidin Completes 50
Oct 24, 2017: Innovation Pharmaceuticals Provides Development Update on Brilacidin for Inflammatory Bowel Disease 51
Oct 18, 2017: Innovation Pharmaceuticals to Complete Phase 2 Trial of Brilacidin for Oral Mucositis in Cancer Patients 52
Oct 02, 2017: Final Patient Completes Treatment in Innovation Pharmaceuticals Phase 2 Trial of Brilacidin for Preventing Oral Mucositis in Cancer Patients 53
Aug 28, 2017: Innovation Pharmaceuticals Completes Full Patient Enrollment in Phase 2b Study of Prurisol for the Oral Treatment of Psoriasis 54
Aug 15, 2017: Innovation Pharmaceuticals to Discuss Recent Positive Clinical Results in IBD and Upcoming Milestones in Oral Mucositis and Psoriasis Trials at BioCentury’s “NewsMakers” Conference 55
Aug 07, 2017: Innovation Pharmaceuticals Completes Patient Enrollment in Phase 2 Study of Brilacidin for the Prevention of Severe Oral Mucositis 56
Jul 13, 2017: Innovation Pharmaceuticals Phase 2 PoC Trial for Inflammatory Bowel Disease Achieves Induction of Remission in a Majority of Patients Treated with Brilacidin 57
Jun 26, 2017: Innovation Pharmaceuticals Completes Treatments in Phase 2 PoC Trial for Induction of Remission in Inflammatory Bowel Disease; Topline Results with Endoscopic Response to Be Presented July 13, 2017 59
May 18, 2017: Cellceutix Completes Patient Enrollment of Final Cohort in Phase 2 Trial of Brilacidin for Inflammatory Bowel Disease; Topline Results Anticipated in July 60
Apr 10, 2017: Cellceutix CEO Discusses Brilacidin Following Interim Trial Results for Treating Oral Mucositis and Inflammatory Bowel Disease 61
Apr 03, 2017: Cellceutix AACR Poster Presents Data Supporting Kevetrin Modulation of p53 in Multiple Human Ovarian Cancer Cell-lines and Corresponding Xenograft Tumors 62
Mar 27, 2017: Cellceutix Reports Very Encouraging Interim Analysis of Phase 2 Drug Candidate Brilacidin for Severe Oral Mucositis in Head and Neck Cancer Patients; High Potential for Preventative Treatment 63
Mar 21, 2017: Cellceutix Releases Favorable Topline Findings as Part of Interim Analysis of Phase 2 Drug Candidate Brilacidin for the Treatment of Inflammatory Bowel Disease 65
Mar 16, 2017: Cellceutix’s Phase 2 Drug Candidate Brilacidin Emerging as a Potential Novel Non-Biologic Therapy in Treating Inflammatory Bowel Disease 67
Mar 08, 2017: Cellceutix Releases Preliminary Efficacy and Safety Data in Interim Analysis of First Two Cohorts in Phase 2 Trial of Brilacidin for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis 68
Mar 03, 2017: Cellceutix Provides Update on Developing p53 Drug Candidate Kevetrin as an Oral Anti-Cancer Agent 69
Feb 22, 2017: Cellceutix Phase 2 Brilacidin Trial Progresses to Highest Dose Cohort for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis 70
Feb 10, 2017: Cellceutix Announces Initiation of Main Clinical Site for Phase 2a Trial of p53 Drug Candidate Kevetrin in the Treatment of Platinum-Resistant/Refractory Ovarian Cancer 71
Jan 23, 2017: Cellceutix’s Brilacidin Demonstrates Promise in Treating Ulcerative Colitis Supported by Endoscopic Assessment, Patient-Reported Outcomes 72
Jan 17, 2017: Cellceutix Completes Enrollment in Second of Three Planned Cohorts in Phase 2 Clinical Trial of Brilacidin for Inflammatory Bowel Disease 73
Other Significant Developments 74
Nov 08, 2018: Innovation Pharmaceuticals provides corporate update highlighting business development and clinical pipeline priorities 74
Sep 20, 2018: Innovation Pharmaceuticals provides corporate update highlighting upcoming milestones and events 75
Jun 07, 2017: Cellceutix Announces Company Name Change to Innovation Pharmaceuticals 76
May 10, 2017: Cellceutix Provides Corporate Update; Significant Milestones Ahead as Multiple Mid-Phase Clinical Trials Set to Conclude 77
Appendix 79
Methodology 79
About GlobalData 79
Contact Us 79
Disclaimer 79

List of Tables
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Innovation Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Innovation Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Cellceutix Enters Into Agreement With University of Texas MD Anderson Cancer Center For Kevetrin Drug 13
Cellceutix Enters Into Licensing Agreement For Cancer Compound 15
Innovation Pharma to Raise up to USD10 Million in Private Placement of Shares 16
Innovation Pharma Raises USD2 Million in Private Placement of Shares 17
Innovation Pharma to Raise USD30 Million in Private Placement of Shares 18
Cellceutix Raises USD16 Million in Private Placement of Common Stock 19
Cellceutix Raises USD2.2 Million in Private Placement of Shares 20
Cellceutix Raises USD20 Million Private Placement Of Common Stock 21
Cellceutix Completes First Tranche Of Private Placement Of Common Stock For USD0.1 Million 22
Cellceutix Completes Private Placement Of Series a Convertible Preference Stock For US$1 Million 24
Cellceutix Completes Acquisition Of PolyMedix 25
Innovation Pharmaceuticals Inc, Key Competitors 26
Innovation Pharmaceuticals Inc, Key Employees 27

List of Figures
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Innovation Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Innovation Pharmaceuticals Inc (IPIX)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Parker Drilling Co (PKD)：企業の財務・戦略的SWOT分析
    Parker Drilling Co (PKD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Petroleos de Venezuela SA：企業の戦略的SWOT分析
    Petroleos de Venezuela SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Crohn’s & Colitis Foundation Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Crohn's & Colitis Foundation Inc (CCF) is a non-profit organization that provides treatments for crohn's disease and ulcerative colitis. The organization funds studies at medical institutions, nurture investigators, and finance underdeveloped areas of research. It provides clinical research …
  • Nimir Industrial Chemical Ltd (NICL)：企業の財務・戦略的SWOT分析
    Summary Nimir Industrial Chemical Ltd (NICL) is a chemical company that manufactures and distributes oleo chemicals and chlor alkali. The company offers products such as stearic acid, soap noodles, glycerin, caustic soda, sodium hypochlorite, and hydrochloric acid, among others. It also provides raw …
  • Mayne Pharma Group Ltd (MYX)：企業の財務・戦略的SWOT分析
    Summary Mayne Pharma Group Ltd (Mayne Pharma) formerly HalcyGen Pharmaceuticals Ltd, is a specialty pharmaceutical company that manufactures and markets branded and generic medicinal products. The company offers products such as erymax capsules, kapanol capsules, doryx capsules, magnoplasm, astrix c …
  • Inter RAO UES (IRAO)：企業の財務・戦略的SWOT分析
    Inter RAO UES (IRAO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Racetrac Petroleum, Inc.
    Racetrac Petroleum, Inc. - Strategy, SWOT and Corporate Finance Report Summary Racetrac Petroleum, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • 3i Group Plc：企業のM&A・事業提携・投資動向
    3i Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's 3i Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Ajinomoto Co Inc (2802)-製薬・医療分野：企業M&A・提携分析
    Summary Ajinomoto Co Inc (Ajinomoto) is a food products company that focuses on foods, bioscience fine chemicals and pharmaceuticals and health. It carries out research and development and production of seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. The …
  • Chevron Corporation (CVX)-石油・ガス分野：企業M&A・提携分析
    Summary Chevron Corporation (Chevron) is an integrated oil and gas company. It operates in the oil and gas value chain from exploration and production, storage and pipeline transportation to refining, marketing and distribution of oil and gas products. Chevron explores for produces and transports cr …
  • CNTEE Transelectrica S.A.：発電所・企業SWOT分析
    CNTEE Transelectrica S.A. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emp …
  • G1 Therapeutics Inc (GTHX)-製薬・医療分野：企業M&A・提携分析
    Summary G1 Therapeutics Inc (G1 Therapeutics), formerly G Zero Therapeutics Inc is a healthcare company that develops novel, and small molecule therapies. The company pipeline products include CDK4/6, trilaciclib G1T28 a drug candidate; G1T38 a potential best compound, and G1T48. It undertakes disco …
  • Gleiss Lutz Hootz Hirsch GmbH：企業の戦略的SWOT分析
    Gleiss Lutz Hootz Hirsch GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Zynerba Pharmaceuticals Inc (ZYNE)：製薬・医療：M&Aディール及び事業提携情報
    Summary Zynerba Pharmaceuticals Inc (Zynerba Pharmaceuticals), formerly AllTranz Inc, is a developer of next-generation synthetic cannabinoid therapeutics. The company provides pipeline product candidates such as ZYN002 and ZYN001. Its ZYN002 is a synthetic CBD, a non-psychoactive cannabinoid, formu …
  • Aiphone Co Ltd (6718)：企業の財務・戦略的SWOT分析
    Aiphone Co Ltd (6718) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • NanoRepro AG (NN6)：製薬・医療：M&Aディール及び事業提携情報
    Summary NanoRepro AG (NanoRepro) is a manufacturer of fast-diagnostics and nutritional food supplements for home and clinical use. The company offers wide range of rapid diagnostic tests products in the areas of family planning, disease detection (preventive healthcare), food intolerances, allergies …
  • BioView Ltd (BIOV)：医療機器：M&Aディール及び事業提携情報
    Summary BioView Ltd (BioView) develops, manufactures and markets automated cell imaging and analysis solutions, which incorporate proprietary imaging, analysis and review technology. The technology provides automatic control of fully motorized fluorescent and bright-field microscopes fitted with hig …
  • Abg Sundal Collier Holding Asa
    Abg Sundal Collier Holding Asa - Strategy, SWOT and Corporate Finance Report Summary Abg Sundal Collier Holding Asa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Okamoto Industries, Inc.：企業の戦略・SWOT・財務情報
    Okamoto Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary Okamoto Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • e.l.f. Beauty, Inc. (ELF)：企業の財務・戦略的SWOT分析
    e.l.f. Beauty, Inc. (ELF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆